📣 VC round data is live. Check it out!
- Public Comps
- Pacira BioSciences
Pacira BioSciences Valuation Multiples
Discover Pacira BioSciences' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like GNI Group, MeiraGTx, Biotest, Keqian Biology and more.
Pacira BioSciences Overview
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Founded
2006
HQ

Employees
790
Website
Financials (LTM)
EV
$1B
Valuation Multiples
Start free trialPacira BioSciences Financials
Pacira BioSciences reported last 12-month revenue of $743M and EBITDA of $185M.
In the same LTM period, Pacira BioSciences generated $593M in gross profit, $185M in EBITDA, and $122M in net income.
Revenue (LTM)
Pacira BioSciences P&L
In the most recent fiscal year, Pacira BioSciences reported revenue of $726M and EBITDA of $186M.
Pacira BioSciences is profitable as of last fiscal year, with gross margin of 79%, EBITDA margin of 26%, and net margin of 17%.
Financial data powered by Morningstar, Inc.
Pacira BioSciences Stock Performance
Pacira BioSciences has current market cap of $902M, and enterprise value of $1B.
Market Cap Evolution
Pacira BioSciences' stock price is $22.93.
Pacira BioSciences share price decreased by 1.3% in the last 30 days, and by 4.0% in the last year.
Pacira BioSciences has an EPS (earnings per share) of $3.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $902M | -1.3% | -1.3% | 1.5% | -4.0% | $3.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPacira BioSciences Valuation Multiples
Pacira BioSciences trades at 1.5x EV/Revenue multiple, and 6.0x EV/EBITDA.
EV / Revenue (LTM)
Pacira BioSciences Financial Valuation Multiples
As of June 2, 2026, Pacira BioSciences has market cap of $902M and EV of $1B.
Pacira BioSciences has a P/E ratio of 7.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pacira BioSciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Pacira BioSciences Margins & Growth Rates
Pacira BioSciences grew revenue by 6% but EBITDA decreased by 1% in the last fiscal year.
In the most recent fiscal year, Pacira BioSciences reported gross margin of 79%, EBITDA margin of 26%, and net margin of 17%.
Pacira BioSciences Margins
Pacira BioSciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pacira BioSciences Operational KPIs
Pacira BioSciences' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.7M for the same period.
Pacira BioSciences' Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pacira BioSciences' Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Pacira BioSciences Competitors
Pacira BioSciences competitors include GNI Group, MeiraGTx, Biotest, Keqian Biology, Annexon, Sana Biotechnology, Supriya Lifescience, Jade Biosciences, Lexicon Pharmaceuticals and SPIMACO - ADDWAEIH.
Most Pacira BioSciences public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.4x | 4.3x | (70.2x) | 423.9x | |||
| 11.3x | 13.6x | (10.3x) | - | |||
| - | - | - | - | |||
| 4.5x | 4.4x | 7.3x | 7.7x | |||
| - | - | (3.3x) | (3.4x) | |||
| - | - | (4.7x) | (4.8x) | |||
| 10.1x | 9.8x | 27.4x | 27.7x | |||
| - | - | (5.3x) | - | |||
This data is available for Pro users. Sign up to see all Pacira BioSciences competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Pacira BioSciences
Pacira BioSciences has acquired 3 companies to date.
Last acquisition by Pacira BioSciences was on February 27th 2025. Pacira BioSciences acquired GQ Bio Therapeutics for $32M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Pacira BioSciences
| Description | GQ Bio Therapeutics is a biotechnology company developing gene therapies and pharmaceuticals targeting osteoarthritis. Headquartered in the United States, it advances intra-articular gene delivery systems to regenerate cartilage and reduce inflammation. The firm's pipeline includes adeno-associated virus vectors delivering therapeutic genes to joint tissues. GQ Bio Therapeutics collaborates on preclinical and clinical programs to address unmet needs in degenerative joint diseases. | Flexion Therapeutics is a biopharmaceutical company specializing in therapies for osteoarthritis and other musculoskeletal disorders. Its FDA-approved product Zilretta delivers extended-release triamcinolone acetonide via intra-articular injection for knee pain management lasting up to three months. Headquartered in Burlington, Massachusetts, Flexion partners with pharmaceutical firms to advance drug candidates from clinical proof-of-concept through commercialization while sharing development risks. The company expanded portfolios through collaborations on injectable therapeutics before its acquisition by Pacira BioSciences in 2022. | MyoScience Inc. is a Redwood City, California-headquartered medical device company developing cryotherapy technologies for aesthetic dermatology. Its core product Cryo-T delivers precise sub-zero temperatures via handheld tips to temporarily freeze sensory nerves, reducing wrinkles in areas like the nasolabial folds and crow's feet. Founded in 2005, the company secured FDA clearance for Cryo-T in 2013 before Allergan acquired it in 2017, integrating the technology into broader aesthetic portfolios. |
| HQ Country | |||
| HQ City | Hamburg | Boston, MA | San Francisco, CA |
| Deal Date | 27 Feb 2025 | 11 Oct 2021 | 5 Mar 2019 |
| Valuation | $32M | $550M | $120M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Pacira BioSciences acquisitions and their M&A valuation multiples. Start Free Trial | |||
Investments by Pacira BioSciences
Pacira BioSciences has invested in 7 companies to date.
Latest investment by Pacira BioSciences was on February 8th 2023. Pacira BioSciences invested in Spine BioPharma in their $13M Series A round (EV/Revenue multiple available to Pro users).
Latest Investments by Pacira BioSciences
| Description | Spine BioPharma advances non-surgical therapies for degenerative spine diseases targeting pain reduction, function restoration, and disease progression halt without opioids. The pipeline includes anti-inflammatory injectables and biologics tested in clinical settings to treat millions affected by chronic back conditions globally. | CarthroniX is a San Diego-based biopharmaceutical company advancing small-molecule drugs for osteoarthritis and cartilage repair. Lead candidate CTX-001 preserves joint matrix while reducing inflammation in preclinical rabbit models. CarthroniX targets knee and hip degeneration with oral therapies entering Phase 1 trials in 2023. | Spine BioPharma advances non-surgical therapies for degenerative spine diseases targeting pain reduction, function restoration, and disease progression halt without opioids. The pipeline includes anti-inflammatory injectables and biologics tested in clinical settings to treat millions affected by chronic back conditions globally. | Genascence is a clinical-stage biotechnology company developing gene therapies for musculoskeletal disorders, particularly osteoarthritis. Based in Pittsburgh, Pennsylvania, the firm delivers genetic payloads via adeno-associated viruses to regenerate cartilage and reduce pain. Its lead candidate targets common knee OA, addressing a condition affecting over 30 million Americans as a risk factor for chronic disability. | |
| HQ Country | |||||
| HQ City | New York City, NY | Lancaster, PA | New York City, NY | San Francisco, CA | |
| Deal Date | 8 Feb 2023 | 11 Apr 2022 | 23 Mar 2022 | 7 Jan 2022 | |
| Round | Series A | Seed | Series B | Series A | |
| Raised | $13M | $2M | $13M | $11M | |
| Investors | Cercano Management; Pacira BioSciences; Viscogliosi Brothers | Pacira BioSciences | Cercano Management; Pacira BioSciences; Viscogliosi Brothers | DeepWork Capital; Pacira BioSciences; Polymerase Capital; University of Florida Research Foundation | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Pacira BioSciences investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pacira BioSciences
| When was Pacira BioSciences founded? | Pacira BioSciences was founded in 2006. |
| Where is Pacira BioSciences headquartered? | Pacira BioSciences is headquartered in United States. |
| How many employees does Pacira BioSciences have? | As of today, Pacira BioSciences has over 790 employees. |
| Who is the CEO of Pacira BioSciences? | Pacira BioSciences' CEO is Frank D. Lee. |
| Is Pacira BioSciences publicly listed? | Yes, Pacira BioSciences is a public company listed on Nasdaq. |
| What is the stock symbol of Pacira BioSciences? | Pacira BioSciences trades under PCRX ticker. |
| When did Pacira BioSciences go public? | Pacira BioSciences went public in 2011. |
| Who are competitors of Pacira BioSciences? | Pacira BioSciences main competitors include GNI Group, MeiraGTx, Biotest, Keqian Biology, Annexon, Sana Biotechnology, Supriya Lifescience, Jade Biosciences, Lexicon Pharmaceuticals, SPIMACO - ADDWAEIH. |
| What is the current market cap of Pacira BioSciences? | Pacira BioSciences' current market cap is $902M. |
| What is the current revenue of Pacira BioSciences? | Pacira BioSciences' last 12 months revenue is $743M. |
| What is the current revenue growth of Pacira BioSciences? | Pacira BioSciences revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Pacira BioSciences? | Current revenue multiple of Pacira BioSciences is 1.5x. |
| What is the current EBITDA of Pacira BioSciences? | Pacira BioSciences' last 12 months EBITDA is $185M. |
| What is Pacira BioSciences' EBITDA margin? | Pacira BioSciences' last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Pacira BioSciences? | Current EBITDA multiple of Pacira BioSciences is 6.0x. |
| What is the current FCF of Pacira BioSciences? | Pacira BioSciences' last 12 months FCF is $140M. |
| What is Pacira BioSciences' FCF margin? | Pacira BioSciences' last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Pacira BioSciences? | Current FCF multiple of Pacira BioSciences is 7.9x. |
| How many companies Pacira BioSciences has acquired to date? | As of June 2026, Pacira BioSciences has acquired 3 companies. |
| What was the largest acquisition by Pacira BioSciences? | $550M acquisition of Flexion Therapeutics on 11th October 2021 was the largest M&A Pacira BioSciences has done to date. |
| What companies Pacira BioSciences acquired? | Pacira BioSciences acquired Flexion Therapeutics, MyoScience, and GQ Bio Therapeutics. |
| In how many companies Pacira BioSciences has invested to date? | As of June 2026, Pacira BioSciences has invested in 7 companies. |
| What was the last Pacira BioSciences investment? | On 8th February 2023 Pacira BioSciences invested in Spine BioPharma, participating in a $13M Series A round, alongside Cercano Management and Viscogliosi Brothers. |
| In what companies Pacira BioSciences invested in? | Pacira BioSciences invested in CODA Biotherapeutics, TELA Bio, Spine BioPharma, Genascence, GeneQuine Biotherapeutics, CarthroniX, and AVALON.AI. |
See public comps similar to Pacira BioSciences
Lists including Pacira BioSciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

